Skip to content

ABRASION WOUND DRESSING USING NANO BIOCELLULOSE WITH BLUE NANO SILVER: A RANDOMIZED, CONTROLLED, ASSESSOR-BLINDED CLINICAL TRIAL STUDY

ABRASION WOUND DRESSING USING NANO BIOCELLULOSE WITH BLUE NANO SILVER: A RANDOMIZED, CONTROLLED, ASSESSOR-BLINDED CLINICAL TRIAL STUDY

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250312011
Enrollment
28
Registered
2025-03-12
Start date
2024-03-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

abrasion wounds Abrasion wounds, Silver Nano Biocellulose, Silver Nano Particles, Wound dressing, Wound healing

Interventions

Test group receives NBBN dressing, the wound will be irrigated with normal saline, then painted with normal saline at the raw wound surface, and painted with povidone iodine at outer wound margin, the
Experimental Other,Active Comparator Other
NANO BIOCELLULOSE WITH BLUE NANO SILVER (NBBN),Conventional wound dressing with normal saline (NSS)

Sponsors

Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang
Lead Sponsor
Chayanin Angthong, MD, PhD
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria includes patient age 18 years and older who presented with an abrasion wound within 24 hours of the accidents. Severity is limited to second-degree abrasion which involves both the epidermis and the dermis or a third-degree abrasion which involves damage that extends to the subcutaneous layer of the skin.

Exclusion criteria

Exclusion criteria: Exclusion criteria include other wound types apart from abrasion wounds such as laceration wound and pressure wound. Abrasion wounds at certain areas such as genitalia and anus are excluded. These areas are areas that are difficult to measure the wound size correctly due to anatomical limitation, and areas that are concerned with patients privacy. Abrasion wounds that occurred more than 24 hours are excluded from this study as well. Patients with specific comorbidities such as disorders requiring long term immunosuppressant drugs, other immunosuppressant patients, and patients with cirrhosis or chronic kidney disease, are excluded as these factors can be confounding factors on wound healing process.

Design outcomes

Primary

MeasureTime frame
wound surface area reduction day 7, 14, 42 ImageJ program

Secondary

MeasureTime frame
vascular endothelial growth factor (VEGF) day 5 VEGF ELISA,Pain Day 7, 14, 42 Visual Analog Scale,Infection day 7, 14, 42 surgical site infection criteria defined by the Centers for Disease Control,Scar day 42 Vancouver scar scale

Countries

Thailand

Contacts

Public ContactKorapin Phatanodom

Faculty of Medicine, King Mongkuts Institute of Technology Ladkrabang

62150012@kmitl.ac.th66818627675

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026